Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Abstract

BACKGROUND: Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. METHODS: In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients were classified as having a favorable outcome at 6 months if they had resolution of clinical disease, a negative culture status, and had not already been classified as having had an unfavorable outcome. Other efficacy end points and safety were also evaluated. RESULTS: A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points. At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid. CONCLUSIONS: The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, NCT02333799.).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 27

1. 1.

   WHO The End TB Strategy. 2014 [cited 2018 09/09/2018]; Available from: http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.

   Not in our library

2. 2.

   Gandhi N.R., et al., Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis, 2012 16(1): p. 90-7.

   Not in our library10.5588/ijtld.11.0153

3. 3.

   Nunn A.J., et al., A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2019 380(13): p. 1201-1213.

   Not in our library10.1056/nejmoa1811867

4. 4.

   Gandhi N.R., et al., Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 2006 368(9547): p. 1575-80.

   Not in our library10.1016/s0140-6736(06)69573-1

5. 5.

   O'Donnell M.R., et al., Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis, 2013 19(3): p. 416-24.

   Not in our library10.3201/eid1903.120998

6. 6.

   Haagsma A.C., et al., Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother, 2009 53(3): p. 1290-2.

   Not in our library10.1128/aac.01393-08

7. 7.

   Pym A.S., et al., Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J, 2016 47(2): p. 564-74.

   Not in our library10.1183/13993003.00724-2015

8. 8.

   Schnippel K., et al., Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med, 2018 6(9): p. 699-706.

   Not in our library10.1016/s2213-2600(18)30235-2

9. 9.

   Lee M., et al., Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med, 2012 367(16): p. 1508-18.

   Not in our library10.1056/nejmoa1201964

10. 10.

    Yang J.S., et al., Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Ann Lab Med, 2018 38(6): p. 563-568.

    Not in our library10.3343/alm.2018.38.6.563

11. 11.

    Singh R., et al., PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science, 2008 322(5906): p. 1392-5.

    Not in our library10.1126/science.1164571

12. 12.

    Manjunatha U., Boshoff H.I., and Barry C.E., The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol, 2009 2(3): p. 215-8.

    Not in our library10.4161/cib.2.3.7926

13. 13.

    Tyagi S., et al., Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother, 2005 49(6): p. 2289-93.

    Not in our library10.1128/aac.49.6.2289-2293.2005

14. 14.

    Stover C.K., et al., A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000 405(6789): p. 962-6.

    Not in our library10.1038/35016103

15. 15.

    Diacon A.H., et al., 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012 380(9846): p. 986-93.

    Not in our library10.1016/s0140-6736(12)61080-0

16. 16.

    Cherry C.L., et al., Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology, 2005 65(11): p. 1778-81.

    Not in our library10.1212/01.wnl.0000187119.33075.41

17. 17.

    DMID, Division of Microbiology and Infectious Diseases, U.S. National Institute of Allergy and Infectious Diseases 2007.

    Not in our library

18. 18.

    WHO, Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. 2018.

    Not in our library

19. 19.

    Ismail N.A., et al., Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine, 2018 28: p. 136-142.

    Not in our library10.1016/j.ebiom.2018.01.005

20. 20.

    WHO, Consolidated guidelines on drug-resistant tuberculosis treatment. Available from https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf, 2019.

    Not in our library

21. 21.

    Collaborative Group for the Meta-Analysis of Individual Patient Data in, M.D.R.T.B.t., et al., Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018 392(10150): p. 821-834.

    Not in our library10.1016/s0140-6736(18)31644-1

22. 22.

    Mbuagbaw L., et al., Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis, 2019 25(5): p. 936-943.

    Not in our library10.3201/eid2505.181823

23. 23.

    Olayanju O., et al., Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J, 2018 51(5).

    Not in our library10.1183/13993003.00544-2018

24. 24.

    Nunn A.J., Phillips P.P., and Mitchison D.A., Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis, 2010 14(2): p. 241-2.

    Not in our library

25. 25.

    Gillespie S.H., et al., Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med, 2014 371(17): p. 1577-87.

    Not in our library10.1056/nejmoa1407426

26. 26.

    Jindani A., et al., High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med, 2014 371(17): p. 1599-608.

    Not in our library10.1056/nejmoa1314210

27. 27.

    Merle C.S., et al., A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med, 2014 371(17): p. 1588-98.

    Not in our library10.1056/nejmoa1315817

Cited by papers we hold 6

• Pathogenicity and virulence of Mycobacterium tuberculosis · 2023
  No notice
• Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019 · 2022
  Not checked
• Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration · 2021
  Not checked
• Type I interferon signaling mediates Mycobacterium tuberculosis –induced macrophage death · 2020
  No notice
• Advances in Molecular Diagnosis of Tuberculosis · 2020
  No notice
• World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.